TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34606551
Drug: 165 mg
Normalized name: aspirin 165 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 mg GHES with 387 mg GTC
Study: 32439492
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-B19 IgM and IgG antibodies
Study: 33846990
Drug: Meloxicam (MLX)
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam (MLX) - IM administration
Study: 33846990
Drug: Meloxicam (MLX)
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam (MLX) - Oral administration
Study: 33846990
Drug: Carprofen (CRP)
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen (CRP) - IM administration
Study: 33846990
Drug: Carprofen (CRP)
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen (CRP) - Oral administration
Study: 33846990
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) - IM administration
Study: 33846990
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) - Oral administration
Study: 34255049
Drug: WMP+Rx (Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: WMP+Rx (Weight Management Program combined with Antiobesity Medication)
Study: 35669487
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (1200 mg calcium + 800 IU vitamin D3 daily)
Study: 33461754
Drug: Intravenous 100
Normalized name: immune globulin intravenous 100 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 100 μg carbetocin
Study: 35938545
Drug: Bipolar Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar Androgen Therapy (BAT)
Study: 38632892
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT)
Study: 32324888
Drug: Itacitinib 200
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 200 mg once daily plus corticosteroids
Study: 32324888
Drug: Itacitinib 300
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 300 mg once daily plus corticosteroids
Study: 32324888
Drug: Itacitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (both doses)
Study: 33272091
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion (maximum of 20,000 units for 24 hours)
Study: 33272091
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion vs No heparin infusion
Study: 35705501
Drug: Cenobamate (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (target dose 300 mg/day; min/max 50/400 mg/day)
Study: 35263841
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal system (GTS)
Study: 34168648
Drug: 4-drug empiric
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug empiric standard TB treatment
Study: 33081449
Drug: N-acetylcysteine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine at a dose of 2000 mg per day for 60 days
Study: 33128535
Drug: Lung rehabilitation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung rehabilitation therapy in combination with routine nursing (observation group)
Study: 33128535
Drug: Lung rehabilitation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung rehabilitation therapy (observation group)
Study: 34325885
Drug: Eplerenone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (100 mg-200 mg)
Study: 35463059
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (2 g/day)
Study: 33288923
Drug: Chimeric hemagglutinin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric hemagglutinin-based vaccines (live-attenuated followed by inactivated vaccine)
Study: 33288923
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal followed by intramuscular)
Study: 33288923
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice intramuscular)
Study: 39534593
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS)
Study: 35049127
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of intervention
Study: 36333954
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (5 mg intravenously)
Study: 32725695
Drug: Blood Flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Flow Restriction (BFR) treatment
Study: 32725695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BFR treatment)
Study: 33297893
Drug: Intravenous argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous argatroban (100 µg/kg bolus followed by 3 µg/kg/min for 12 h)
Study: 33297893
Drug: Intravenous eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous eptifibatide (135 µg/kg bolus followed by 0.75 µg/kg/min infusion for 2 h)
Study: 32149759
Drug: Carbetocin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 50 µg (C50)
Study: 32149759
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 µg (C100)
Study: 35837833
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg)
Study: 35790333
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics
Study: 35605529
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR‐NTX)
Study: 38232249
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only
Study: 32350413
Drug: Sequential nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential nab-paclitaxel plus gemcitabine (SEQ)
Study: 34406329
Drug: Office-based vergence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence accommodative therapy (OBVAT)
Study: 39673334
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy
Study: 35568909
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies
Study: 32777617
Drug: brief cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief cognitive‐behavioral therapy (CBT) for suicide prevention
Study: 35977548
Drug: Abaloparatide 80
Normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 80 µg daily subcutaneous for 78 weeks
Study: 36478476
Drug: Orismilast IR
Normalized name: Orismilast
DrugBank: Orismilast (DB19042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orismilast IR 30 mg
Study: 34958306
Drug: Precision SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision SMS text messages (stage-targeted educational information, next dose due date, site-specific walk-in hours)
Study: 32545396
Drug: Ambrotose Advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrotose Advanced (AA) at 2 or 4 g daily
Study: 32545396
Drug: Ambrotose LIFE
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrotose LIFE (AL) at 2 or 4 g daily
Study: 38916892
Drug: Sublingual buprenorphine-naloxone
Normalized name: buprenorphine / naloxone Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine-naloxone
Study: 32115328
Drug: Anesthesiologist administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesiologist administered ACB (group 1)
Study: 32115328
Drug: Surgeon administered
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon administered ACB (group 2)
Study: 34982493
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day oral isotretinoin
Study: 35101419
Drug: Standard-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose warfarin
Study: 36449420
Drug: Deferiprone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (15 mg/kg twice daily)
Study: 33578001
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) administered ≤4 weeks postoperatively
Study: 33578001
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) administered >4 weeks postoperatively
Study: 32152170
Drug: CBD 20
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 20 mg/kg/day
Study: 35083234
Drug: Intravitreal conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal conbercept injection
Study: 33152282
Drug: Angiogenesis inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiogenesis inhibitors
Study: 32524612
Drug: Labeled glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled glass (340-ml glasses of beer or wine)
Study: 32524612
Drug: Plain glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain glass (control, 340-ml glasses of beer or wine)
Study: 33625666
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy for 3 months in addition to pharmacological treatment
Study: 32281269
Drug: Physical therapy‐led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy‐led pathway
Study: 39306665
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg)
Study: 35283116
Drug: Synthetic ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic ACTH (1 mg)
Study: 35283116
Drug: Betamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (6 mg)
Study: 32150492
Drug: Epinephrine CFC
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine CFC MDI (220 μg/inhalation)
Study: 35428609
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg/kg on day 1, followed by 80 mg/kg on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Study: 35428609
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg/kg on day 1 and placebo on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Study: 32537707
Drug: Multi-component training
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component training (including dual-task, dynamic balance, endurance and strength exercises) for 16 weeks (twice per week for 45–60 min)
Study: 38456441
Drug: Multiple Daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Daily Injections (MDI)
Study: 35567889
Drug: Probiotic (Vivomix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Vivomix 112 billion, one capsule a day for 16 weeks)
Study: 32911306
Drug: teriflunomide 14
Normalized name: teriflunomide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriflunomide 14 mg/14 mg
Study: 36454520
Drug: Drug-related readmission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related readmission within 12 months post-discharge
Study: 36454520
Drug: Potentially preventable
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially preventable drug-related revisits
Study: 32649736
Drug: Entecavir treatment
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir treatment
Study: 35791646
Drug: DBPR108 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPR108 + metformin
Study: 32631447
Drug: 1:1 delta-9-tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation.
Study: 32631447
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral solution).
Study: 33676886
Drug: Personalized digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized digital and human direct oral anticoagulant adherence intervention (medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence)
Study: 32838353
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antiviral medication)
Study: 34127032
Drug: Robotic rehabilitation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic rehabilitation using G-EO system
Study: 35337743
Drug: Landiolol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.5, 1, 2, 5, and 10 μg/kg/min)
Study: 33316626
Drug: EPA 4
Normalized name: krill oil/omega-3/dha/epa 45 mg-45 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA 4 g/d
Study: 33316626
Drug: EPA 1
Normalized name: thiotepa 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA 1 g/d
Study: 33316626
Drug: EPA 2
Normalized name: docosahexaenoic acid/epa 250 mg-100 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA 2 g/d
Study: 35410590
Drug: PartoMa intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PartoMa intervention (co-created clinical practice guidelines and low-dose, high-frequency training)
Study: 33431052
Drug: High-dose saccharin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose saccharin supplementation (administered in capsules twice daily for 2 weeks)
Study: 33431052
Drug: High-dose saccharin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose saccharin supplementation
Study: 32004499
Drug: Type-IV resistant
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type-IV resistant starches (RS4s), specifically crystalline and phosphate cross-linked starch structures, administered at a dose of 35 g/day.
Study: 35991892
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone PCA (0.05 mg/h with 0.2 mg on-demand)
Study: 35991892
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone PCA
Study: 34533832
Drug: 1% metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metformin gel plus platelet-rich fibrin (PRF)
Study: 33543637
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review with follow-up
Study: 32221052
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy
Study: 36261752
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment
Study: 32726003
Drug: Huoxiang Zhengqi
Normalized name: HYPOCHLOROUS ACID 100 mg in 500 mL EXTRACORPOREAL LIQUID [Huoting slight acid hypochlorite disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules
Study: 33581920
Drug: QVLP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVLP (30 μg HA/strain) from three sequential lots
Study: 33258553
Drug: Tofacitinib 11
Normalized name: tofacitinib 11 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 11 mg XR daily
Study: 36427600
Drug: Levonorgestrel 52‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52‐mg intrauterine device
Study: 34033266
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray
Study: 32065672
Drug: Diazepam rectal
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam rectal gel
Study: 33580745
Drug: MR-OA (90/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-OA (90/30 mg orlistat/mg acarbose)
Study: 33580745
Drug: MR-OA (120/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-OA (120/40 mg orlistat/mg acarbose)
Study: 33580745
Drug: Conventional orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional orlistat (Xenical, 120 mg)
Study: 33421559
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (2 g)
Study: 33543897
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 units intravenous alone
Study: 33543897
Drug: Oxytocin plus
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin plus carboprost 0.25 mg intramuscular
Study: 33605002
Drug: Intralesional botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional botulinum toxin type-A (BTX-A) injection
Study: 35120640
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (4-days-on and 3-days-off regimen)
Study: 33790017
Drug: Deworming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming treatment (two to three additional years)
Study: 35939083
Drug: Psilocybin-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted therapy (n = 27)
Study: 34331678
Drug: Daridorexant 200
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant 200 mg
Study: 32744034
Drug: RBX Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX Chinese herbal tablets (CHT)
Study: 33436442
Drug: Intravenous dexmedetomidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine, intravenous magnesium, intrathecal morphine, quadratus lumborum blocks, paravertebral nerve blocks, continuous local anesthetic wound infiltration, postoperative interpleural local anesthesia
Study: 33436442
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, ketamine, dexamethasone, gabapentinoids
Study: 33894832
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (0.8 mA, 100 μs, 30 Hz stimulation pulses, lasting 0.5 s) paired with rehabilitation (6 weeks of in-clinic therapy, three times per week, followed by home exercise programme)
Study: 35963261
Drug: Levetiracetam (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (intravenous 500 mg every 12 h for 6 weeks)
Study: 36229710
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral SERDs
Study: 32762340
Drug: OM-89 immunotherapy
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-89 immunotherapy (6 mg), once daily for 3 months
Study: 32762340
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 3 months
Study: 34032803
Drug: Guided internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet delivered cognitive behavioural treatment (CBT) for insomnia
Study: 34489388
Drug: Opioid medications
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid medications
Study: 34464304
Drug: Preoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative physical therapy education program
Study: 34112719
Drug: MRI (absent/equivocal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI (absent/equivocal signal in the posterior limb of the internal capsule)
Study: 33674187
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in 6-IHC score 'High' risk group
Study: 33674187
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in 6-IHC score 'Low' risk group
Study: 32678376
Drug: Weighted blanket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted blanket during chemotherapy infusion
Study: 32678376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no weighted blanket during chemotherapy infusion)
Study: 32989261
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiST) - 5000 shockwaves per session with energy flux density 0.1 mJ/mm2, 6 sessions (once/week)
Study: 32989261
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 5000 shockwaves from a visually identical sham probe, 6 sessions (once/week)
Study: 33188493
Drug: Epidural dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural dexmedetomidine (0.1% ropivacaine with 0.5 µg/mL dexmedetomidine)
Study: 35122766
Drug: Higher induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3)
Study: 35122766
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2)